Kura Oncology Inc (NAS:KURA)
$ 8.86 -0.08 (-0.89%) Market Cap: 688.99 Mil Enterprise Value: 250.32 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 29/100

Kura Oncology Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 12, 2020 / 07:40PM GMT
Release Date Price: $15.2 (-2.06%)
Operator

Hello. This webcast presentation is for Bank of America clients only. If you are a member or representative of the press or media, please disconnect now. And now I would like to turn the call over to the analyst. Thank you.

Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Thank you, and good day, everybody. And hi, my name's Jason Gerberry, and I cover SMID cap biotech at Bank of America. I am pleased to be introducing our next company presenter, Kura Oncology; and Troy Wilson, President and CEO.

For those of you unfamiliar, Kura is a clinical stage oncology company focused on precision medicines, and Troy is going to walk you through the corporate presentation and talk about some of the interesting clinical programs in development. So Troy, I'll turn it over to you.

Troy Edward Wilson
Kura Oncology, Inc. - Chairman, CEO & President

Great. Thank you, Jason. I appreciate the introduction and appreciate the invitation from Bank of America Securities today.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot